Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.86 |
| ▸ | CHAT | P28329 | 2/20 | 0.82 |
| ▸ | EP300 | Q09472 | 4/20 | 0.81 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.81 |
| ▸ | AURKA | O14965 | 2/20 | 0.81 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.81 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14992960 | 1.00 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL30221076 | 1.00 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL31099185 | 0.97 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL20815900 | 0.97 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL168546 | 0.97 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL726402 | 0.96 | NAA50 (0.82) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL29896426 | 0.96 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL20608400 | 0.96 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL16915362 | 0.96 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL20815901 | 0.96 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12213956-B2 | Method of treating fatty acid oxidation disorders using omega3/omega6 unsaturated or branched chain fatty acids | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-02-04 | — | — | US | disclosed |
| US-11844775-B2 | Method of treating fatty acid oxidation disorders using Omega3/Omega6 unsaturated or branched chain fatty acids | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-12-19 | — | — | US | disclosed |
| CN-113278597-B | Novel short side chain fatty acid CoA ligase and application thereof in preparation of patchoulenone | 重庆大学 | 2023-04-21 | — | — | CN | disclosed |
| US-20210353581-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-11-18 | — | — | US | disclosed |
| US-20210322357-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-10-21 | — | — | US | disclosed |
| CN-113278597-A | Novel short-side-chain fatty acid CoA ligase and application thereof in preparation of patchoulenone | 重庆大学 | 2021-08-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353581-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | ELOVL6, ELOVL3, CPT1B | NAA50 992/4885CHAT 1429/4885EP300 2700/4885 |
| US-11844775-B2 | Method of treating fatty acid oxidation disorders using Omega3/Omega6 unsaturated or branched chain fatty acids | ELOVL6, ELOVL3, CPT1B | NAA50 986/4885CHAT 1405/4885EP300 2618/4885 |
| US-20210322357-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | ELOVL6, ELOVL3, CPT1B | NAA50 986/4885CHAT 1405/4885EP300 2618/4885 |
| US-12213956-B2 | Method of treating fatty acid oxidation disorders using omega3/omega6 unsaturated or branched chain fatty acids | ELOVL6, ELOVL3, CPT1B | NAA50 992/4885CHAT 1429/4885EP300 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.